Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats

Neuroscience Letters

Volumn 361, Issue 1-3, 2004, Pages 56-59

  Liang, Yan Qi ^a   Tang, Xi Can ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Acetylcholine; Acetylcholinesterase; Alzheimer's disease; Donepezil; Huperzine A; Rat; Rivastigmine

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; DONEPEZIL; HUPERZINE A; RIVASTIGMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN REGION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FASCICULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; ANIMALS; BRAIN CHEMISTRY; CARBAMATES; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FASCICULATION; INDANS; MALE; NEURONS; PHENYLCARBAMATES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; UP-REGULATION;

EID: 2342636400     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2003.12.071     Document Type: Article

References (22)

1. Ballard T.M., McAllister K.H. The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats. Psychopharmacology. 146:1999;10-18
2. Bar-On P., Millard C.B., Harel M., Dvir H., Enz A., Sussman J.L., Silman I. Kinetic and structural studies on the interaction of cholinesterase with the anti-Alzheimer drug rivastigmine. Biochemistry. 41:2002;3555-3564
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254
4. Cheng D.H., Ren H., Tang X.C. Huperzine A, a novel promising acetylcholinesterase inhibitor. NeuroReport. 8:1996;97-101
5. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190
6. Ellman G.L., Courtney K.D., Andre V. Jr, Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95
7. Giacobini E., Becker R. Development of drugs for Alzheimer therapy: a decade of progress. Giacobini E., Becker R. Alzheimer Disease: Therapeutic Strategies. 1994;1-7 Birkhäuser, Boston, MA
8. Giacobini E., Cuadra G. Second and third generation cholinesterase inhibitors: from preclinical studies to clinical efficacy. Giacobini E., Becker R. Alzheimer Disease: Therapeutic Strategies. 1994;155-171 Birkhäuser, Boston, MA
9. Giacobini E., Zhu X.D., Williams E., Sherman K.A. The effect of the selective reversible acetylcholinesterase E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology. 35:1996;205-211
10. Greaney M.D., Marshall D.L., Bailey B.A., Acworth I.N. Improved method for the routine analysis of acetylcholine release in vivo: quantitation in the presence and absence of esterase inhibitor. J. Chromatogr. B. 622:1993;125-135
11. Kosasa T., Kuriya Y., Matsui K., Yamanishi Y. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur. J. Pharmacol. 380:1999;101-107
12. Messamore E., Warpman U., Ogane N., Giacobini E. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex. Neuropharmacology. 32:1993;745-750
13. Rogers S.L., Yamanishi Y., Yamatsu K. E2020: the pharmacology of a piperidine cholinesterase inhibitor. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;314-320 Birkhäuser, Boston, MA
14. Scali C., Casamenti F., Bellucci A., Costagli C., Schmidt B., Pepeu G. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J. Neural Transm. 109:2002;1067-1080
15. Sherman K.A., Messamore E. Blood cholinesterase as a guide to the efficacy of putative therapies for Alzheimer dementia: comparison of tacrine and physostigmine. Giacobini E., Becker R. Current Research in Alzheimer Therapy. 1988;73-86 Taylor and Francis, New York
16. Tang X.C. Huperzine A (Shuangyiping): A promising drug for Alzheimer's disease. Acta Pharmacol. Sin. 17:1996;481-484
17. Tang X.C., He X.C., Bai D.L. Huperzine A: a novel acetylcholinesterase inhibitor. Drugs Fut. 24:1999;647-663
18. Taylor P. Anticholinesterase agents. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th Edition:1996;161-176 McGraw-Hill, New York
19. Trabace L., Coluccia A., Gaetani S., Tattoli M., Cagiano R., Pietra C., Kendrick K.M., Cuomo V. In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus. Brain Res. 865:2000;268-271
20. Weinstock M., Razin M., Chorev M., Enz A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J. Neural Transm. 43:1994;219-225
21. Zhao Q., Tang X.C. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur. J. Pharmacol. 455:2002;101-107
22. Zhu X.D., Giacobini E. Second generation cholinesterase inhibitors: effect of (L)-huperzine-A on cortical biogenic amines. J. Neurosci. Res. 41:1995;828-835